At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 46 enrolled
Drug / intervention
Alogliptindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Comparative, Randomized, Open-Label, Multi-Center, Single Dose Pharmacokinetic, Pharmacodynamic and Safety Study of Alogliptin (12.5 mg and 25 mg) Between Children, Adolescents, and Adults With Type 2 (Non-Insulin Dependent) Diabetes Mellitus
In Brief
A Phase 1 clinical trial evaluating Alogliptin for Diabetes Mellitus, Type 2. Completed, enrolled 46 participants across 7 sites.
Detailed Summary
The purpose of this study is to determine the pharmacokinetic and safety profile of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2009
Enrollment StartSep 2009
Primary CompletionNov 2013
TodayJul 2026
First PostedAug 12, 2009
Enrollment StartSep 1, 2009
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 16.9 years ago
Interventions
Alogliptindrug
Alogliptin tablets